Literature DB >> 10639877

Building and testing an effective HIV vaccine.

J Kahn1.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10639877      PMCID： PMC1308762     

Source DB:  PubMed          Journal:  West J Med        ISSN： 0093-0415


× No keyword cloud information.
  16 in total

1.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

Review 2.  Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials.

Authors:  M A Chesney; P Lurie; T J Coates
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-05-01

3.  Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials.

Authors:  S Scheer; J M Douglas; E Vittinghoff; B N Bartholow; D McKirnan; F N Judson; K M MacQueen; S Buchbinder
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-02-01

4.  Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials.

Authors:  R B Hays; S M Kegeles
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1999-02-01

5.  Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial.

Authors:  J O Kahn; K S Steimer; J Baenziger; A M Duliege; M Feinberg; T Elbeik; M Chesney; N Murcar; D Chernoff; F Sinangil
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

6.  Incentives and disincentives to participate in prophylactic HIV vaccine research.

Authors:  R A Jenkins; L R Temoshok; K Virochsiri
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-05-01

7.  Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States.

Authors:  B A Koblin; P Heagerty; A Sheon; S Buchbinder; C Celum; J M Douglas; M Gross; M Marmor; K Mayer; D Metzger; G Seage
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

8.  Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial.

Authors:  A R Sheon; L Wagner; M J McElrath; M C Keefer; E Zimmerman; H Israel; D Berger; P Fast
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998-12-15

9.  Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R B Belshe; B S Graham; M C Keefer; G J Gorse; P Wright; R Dolin; T Matthews; K Weinhold; D P Bolognesi; R Sposto
Journal:  JAMA       Date:  1994-08-10       Impact factor: 56.272

Review 10.  Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

Authors:  D P Francis; T Gregory; M J McElrath; R B Belshe; G J Gorse; S Migasena; D Kitayaporn; P Pitisuttitham; T Matthews; D H Schwartz; P W Berman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-10       Impact factor: 2.205
View more
  1 in total

Review 1.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.